LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "nyha class" as a keyword



Photo by shotsbywolf from unsplash

Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study

Sign Up to like & get
recommendations! Published in 2023 at "ESC Heart Failure"

DOI: 10.1002/ehf2.14273

Abstract: Patients with severe mitral regurgitation (MR) and acute heart failure (HF) have refractory symptoms without adequate response to medical therapy. The objective of this analysis was to assess the impact of the MitraClip device in… read more here.

Keywords: nyha class; mitraclip; acutely ill; mitral regurgitation ... See more keywords
Photo by freestocks from unsplash

Bone mineral density in older patients with chronic heart failure is related to NYHA classification: a retrospective study

Sign Up to like & get
recommendations! Published in 2018 at "European Geriatric Medicine"

DOI: 10.1007/s41999-018-0027-5

Abstract: PurposeDiscrepant results on relationship between chronic heart failure (CHF) and bone mineral density (BMD) have been reported and little has investigated the association between bone mass loss and New York Heart Association (NYHA) classification in… read more here.

Keywords: heart; nyha classification; class; bmd ... See more keywords
Photo by shotsbywolf from unsplash

New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials

Sign Up to like & get
recommendations! Published in 2017 at "American Heart Journal"

DOI: 10.1016/j.ahj.2017.06.002

Abstract: Background Primary prevention implantable cardioverter defibrillator (ICD) reduce all‐cause mortality by reducing sudden cardiac death. There are conflicting data regarding whether patients with more advanced heart failure derive ICD benefit owing to the competing risk… read more here.

Keywords: class; mortality; icd; primary prevention ... See more keywords
Photo by myriamzilles from unsplash

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Sign Up to like & get
recommendations! Published in 2020 at "The Lancet"

DOI: 10.1016/s0140-6736(20)31792-x

Abstract: BACKGROUND Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated… read more here.

Keywords: placebo; treatment; obstructive hypertrophic; nyha class ... See more keywords
Photo by shotsbywolf from unsplash

Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy

Sign Up to like & get
recommendations! Published in 2020 at "European Heart Journal"

DOI: 10.1093/ehjci/ehaa946.2115

Abstract: In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis was shown to be an effective treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Further assessment of the efficacy of tafamidis in patients with more… read more here.

Keywords: patients advanced; tafamidis patients; class iii; tafamidis ... See more keywords
Photo from wikipedia

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group

Sign Up to like & get
recommendations! Published in 2018 at "Rheumatology"

DOI: 10.1093/rheumatology/kex182

Abstract: Objectives The multisystem manifestations of SSc can greatly impact patients' quality of life. The aim of this study was to identify factors associated with disability in SSc. Methods SSc patients from the prospective DeSScipher cohort… read more here.

Keywords: disability; shaq; study; desscipher ... See more keywords
Photo from wikipedia

Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure

Sign Up to like & get
recommendations! Published in 2023 at "Frontiers in Cardiovascular Medicine"

DOI: 10.3389/fcvm.2022.1076806

Abstract: Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of… read more here.

Keywords: nyha class; chronic heart; heart failure; heart ... See more keywords